Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Christine Ryan
- Target Recruit Count
- 66
- Registration Number
- NCT06043674
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
- Conditions
- Interventions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Isala
- Target Recruit Count
- 679
- Registration Number
- NCT06031233
- Locations
- 🇳🇱
Isala Hospital, Zwolle, Netherlands
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT06031441
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
🇨🇦British Columbia Cancer Agency - 600 10th Ave W, Vancouver, British Columbia, Canada
LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 37
- Registration Number
- NCT06012734
- Locations
- 🇳🇱
Antoni van Leeuwenhoek, Amsterdam, Noord Holland, Netherlands
A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT06006286
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Omico
- Target Recruit Count
- 96
- Registration Number
- NCT06003621
- Locations
- 🇦🇺
Border Medical Oncology Research Unit, Albury, New South Wales, Australia
🇦🇺Ramsay Health Care Australia Pty Ltd trading as The Border Cancer Hospital, Albury, New South Wales, Australia
🇦🇺Coffs Harbour Health Campus, Coffs Harbour, New South Wales, Australia
Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 21
- Registration Number
- NCT05999812
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT05968326
- Locations
- 🇪🇸
Centro Integral Oncológico Clara Campal Ensayos Clínicos START, Madrid, Spain
🇬🇧Addenbrookes Hospital; Cambridge Cancer Trials Centre, S4 Box 279, Cambridge, United Kingdom
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 219
- Registration Number
- NCT05907980
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸NEXT Oncology, Fairfax, Virginia, United States
🇯🇵National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 150
- Registration Number
- NCT05908786
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
🇺🇸University of Southern California (USC); Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California Los Angeles (UCLA) - Cancer Care - Santa Monica, Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.